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Selective, non-covalent conjugation of synthetic
peptides with recombinant proteins mediated by
host–guest chemistry†
R. J. Gubeli,a S. Sonzini,b A. Podmore,a P. Ravn,c O. A. Scherman*b and
C. F. van der Walle*a
The combination of potent chemical moieties with biologically active
proteins is key to some of today’s most innovative therapeutic drugs.
In order to obviate any chemical modification of the proteins, we
present a novel and powerful strategy for the selective conjugation
of recombinant protein domains with synthetically derived peptides
via a cucurbit[8]uril host–guest chemistry approach.
The conjugation of proteins with chemically synthesised moieties
represents a rapidly growing strategy for the generation of highly
potent therapeutic drugs. Notably, improved tissue target selectivity
of cytotoxic drugs has been achieved by conjugation to immuno-
globulins,1 and the in vivo stability of peptides is increased by
fusion to immunoglobulin Fc (Fragment, crystallisable).2 A key
challenge during the design and development of these conjugates
is the selection of a suitable chemistry to link the synthetic
molecule to the recombinant protein.3 In order to elicit a robust
and reproducible therapeutic eﬀect, a uniformmolecule to protein
ratio should be achieved without compromising drug potency.
Recent eﬀorts have been focused on selectively addressing one or
several functional groups on the protein surface, most commonly
cysteine or lysine side chains.1,4 On account of the complexity of
the protein surface such covalent conjugation strategies, especially
involving lysine, may lead to heterogeneous products which
necessitate additional optimisation steps for each molecule–
protein combination.5
Host–guest chemistry represents an alternative, non-covalent
approach for the conjugation of synthetic molecules to recombinant
proteins and has the advantage of being straightforward and
selective. Various hosts have been applied in supramolecular
assemblies to direct synthetic molecules to distinct guest groups
on the protein surface, including calixarenes,6 and cyclodextrins.7
More recently, cucurbit[n]urils have emerged as a family of hosts
able to bind to guest molecules with unprecedented (up to
femtomolar) affinity.8,9 Cucurbit[8]uril (CB[8]) has a large cavity
size and so possesses the unusual ability to accommodate two
guests simultaneously, commonly forming a charge-transfer
complex between an electron-poor 1st guest and an electron-
rich 2nd guest (Fig. 1A).10–12 CB[8] has been applied to the
assembly of polymer–protein13 and protein–protein14 conju-
gates, but in these studies derivatisation of the protein with
guest moieties was necessary prior to the host–guest assembly.
A strategy avoiding protein derivatisation while still facilitating
host–guest assembly would be much more straightforward and
advantageous for biological applications.
Inspired by studies showing that CB[8]-mediated hetero-
dimeric complexes can be formed with tryptophan (Trp) residues
in short peptides15,16 we reasoned that CB[8] could be capable of
Fig. 1 Non-covalent conjugation of synthetic peptides with recombinant
protein domains mediated by CB[8]. (A) Molecules harbouring a 1st guest
moiety such as a methyl viologen derivative (MV) are specifically linked to
N-terminal tryptophan (Trp; 2nd guest) residues on recombinant proteins
by ternary complexation with the host CB[8]. (B) Peptide-Fc conjugations
are generated by CB[8]-mediated assembly of Fc domains with synthetic
peptides. The MV derivative was used as a trifluoroacetate salt (counter-
ion not shown in the cartoon).
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conjugating derivatised peptide molecules to proteins appended
with a Trp ‘tag’. This selective heterodimerisation strategy is
distinct from the CB[8] mediated polymerisation of Phe-Gly-Gly
(FGG)-tagged glutathione-S-transferase17 and homodimerisation
of FGG-tagged yellow fluorescent protein.18 Thus, we show that
synthetic peptides derivatised with methyl viologen (MV) (the 1st
guest) can be addressed to a specific Trp residue (the 2nd guest)
at the protein surface via CB[8], forming a heteroternary complex
(Fig. 1A). Using stopped-flow spectroscopy, we reveal the fast
exchange kinetics that lead to the considerably high aﬃnity of
the ternary complex. Furthermore, we demonstrate that the
protein-bound synthetic peptide maintains its functional activity
towards its receptor target. By pioneering the CB[8]-mediated
conjugation of synthetic molecules to recombinant proteins,
this study paves the way to the design and development of
next-generation therapeutics with enhanced properties provided
by host–guest chemistry.
Trp is a hydrophobic amino acid, which generally favours
internalisation in a folded protein; the establishment of a hydro-
phobic core is a key driver in the folding pathway of proteins.19
Therefore, in order to avoid protein conformational destabilisation,
we genetically engineered a spacer consisting of four tetraglycine-
serine repeats between the protein body and the N-terminal 2nd
guest Trp residue. Placing the Trp at the N-terminus of the protein
also served to further stabilise the ternary host–guest assembly by
facilitating interaction of the positively charged amino group with
the carbonyl groups at the rim of CB[8].15 In selecting a protein
for conjugation, we chose the immunoglobulin Fc since it is
therapeutically relevant,20 imparting desired biophysical stability
and pharmacokinetic properties.21 The Fc domain naturally
predominates as a covalently linked homodimer, thereby pre-
senting two N-termini, which we genetically modified with Trp
residues as 2nd guests for the host–guest assembly (Fig. 1B). For
the synthetic molecule to be conjugated to the Fc domain, we
selected linear and cyclic arginine–glycine–aspartic acid (RGD)
peptides derivatised with MV (RGD-MV and cRGD-MV, respec-
tively, Fig. S1A, ESI†). RGD is the canonical ligand of the integrin
avb3 receptor and its cyclic form led to the development of
cilengitide, the first anti-angiogenic small molecule drug.22
Previous studies have shown that the association of RGD with
nanoparticles and proteins can enhance their diagnostic and
therapeutic benefits.23,24 It is noteworthy that the synthetic routes
to peptidomimetics, which involve cyclisation and/or D-amino acids,
preclude their genetic conjugation to proteins. The CB[8]-mediated
host–guest assembly can achieve the conjugation of such peptido-
mimetics to proteins in an elegant manner, here resulting in a
heteroternary supramolecular complex of 2 peptides bound viaCB[8]
to each N-terminal Trp of the Fc domain (Fig. 1B). We started
analysing the sequential assembly of the ternary complex by
isothermal titration calorimetry (ITC).
The precomplex of cRGD-MV with CB[8] was formed with a
1 : 1 stoichiometry and an equilibrium binding constant (Ka:
6.3  105 M1, Fig. S2, ESI†) which is in accordance to previous
observations with MV-modified peptides.16 In a subsequent
step, we tested the binding of the cRGD MVCCB[8] precomplex
to the two N-terminal Trp guests of the recombinant Fc domain
(Fig. 2A, thermodynamic data in Table 1 and Table S1, ESI†).
We were able to confirm a 1 : 1 : 1 stoichiometry of the host with
the 1st and 2nd guest moieties, resulting in a molecular
architecture wherein every Fc domain was conjugated with
two cRGD-MV peptides ((cRGD MVCCB[8])2CTrp-Fc).
The precomplex cRGD-MVCCB[8] interacted with the 2nd
guest Trp with a Ka of 2.3  105 M1 resulting from an enthalpi-
cally favourable contribution and an entropic penalty (Table S1,
ESI†), thereby confirming that we were able to transfer the
binding characteristics observed with Trp in a short 3-amino acid
oligopeptide15 to the 3-dimensionally folded Fc domain.
When we exchanged the N-terminal Trp residues of the Fc
domain with tyrosine (Tyr-Fc, Fig. S4A, ESI†), a 10-fold decrease
in aﬃnity was observed. Furthermore, an Fc domain with N
terminal serines (Ser-Fc, Fig. S4B, ESI†) did not show any
interaction with the cRGD-MVCCB[8] precomplex.
This indicates that the host–guest assembly is directed
with high specificity towards the exposed N-terminal residues
while excluding the other 8 Trp, 18 Tyr and 16 Phe residues,
which are part of the hydrophobic core of the Fc domain
(Fig. S5, ESI†).
Fig. 2 Formation of CB[8]-mediated peptide-Fc conjugations. (A) Binding
of cRGD-MVCCB[8] precomplex (500 mM, 36.5 mL in over 19 injections) to
Fc domain harbouring N-terminal tryptophans (Trp-Fc, 50 mM) charac-
terised by ITC (Fc-domain purity is shown in Fig. S3, ESI†). (B) Changes in
tryptophan fluorescence of Trp-Fc (50 mM) were followed by the addition
of equimolar amounts of cRGD-MV and CB[8] alone or in precomplex
(cRGD-MVCCB[8]).
Table 1 Kinetic and thermodynamic constants for ternary complex for-
mation of cRGD-MVCCB[8] with Trp-Fc
Temperature
[1C]
Ka (ITC)
a
[105; M1]
ka
[106; M1 s1]
kd
[s1]
Ka
b
[105; M1]
7.5 2.7  0.1 29  1 89  15 3.3  0.7
10 2.6  0.2 34  2 105  23 3.2  0.6
15 2.5  0.2 41  2 131  24 3.1  0.6
37 2.3  0.3 98  16c 364  42c 2.7  0.5
a Equilibrium binding constants determined by ITC and separately.
b Equilibrium binding constants calculated from the ratio of ka to kd.
c Kinetic constants extrapolated from measured values at lower tem-
perature using the Arrhenius law.
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To further demonstrate the selective CB[8] mediated assem-
bly of the heteroternary complex, we followed the change in
intrinsic Trp fluorescence of the Fc domain (Fig. 2B). Whereas
the addition of cRGD-MV or CB[8] alone only led to a slight
decrease in fluorescence, the quenching was much greater upon
addition of the cRGD-MVCCB[8] precomplex. This, together
with a less evident hypsochromic eﬀect caused by the addition
of the precomplex compared to CB[8] alone, indicates that the
two guests indeed form a charge-transfer complex inside the
CB[8] cavity.25
In agreement with thermodynamic characterisation by
ITC, no significant Trp fluorescence quenching eﬀect of the
cRGD-MVCCB[8] precomplex or its single components could
be observed upon incubation with Ser-Fc (Fig. S6, ESI†), again
confirming that the host–guest assembly does not interfere
with the folded structure of the Fc domain itself.
In an assay designed to be independent of the nature of the
host and guest molecules, we monitored the change in mole-
cular size of the synthetic peptide during the assembly of the
ternary complex by fluorescence polarisation (Fig. S7, ESI†).
With this aim, we synthesised a linear RGD-MV peptide covalently
modified with fluorescein at the N-terminus (FITC-RGD-MV,
Fig. S1B, ESI†). The addition of increasing concentrations of
CB[8] to FITC-RGD-MV (300 nM) resulted in an increase in polarisa-
tion of the FITC fluorophore at a CB[8] concentration around 1 mM,
which agrees well with the dissociation constant (Kd = 1/Ka = 1.6 mM)
of the precomplex as measured by ITC. In a second step, we titrated
Trp-Fc into a solution of assembled FITC-RGD-MVCCB[8] and again
observed an increase in polarisation at a Trp-Fc concentration
corresponding to the measured Kd of 5.2 mM for the ternary complex
(Fig. S7, ESI†). Interestingly, at Trp-Fc concentrations higher than
15 mM, polarisation decreased again, which can be explained by the
inclusion of two Trp moieties into the CB[8] host.26 Although such a
homodimeric Trp2CCB[8] complex is of lower aﬃnity as compared
to the heterodimeric assembly, its partial formation can be detected
in this assay due to the high molar excess of Trp-Fc over the
MV-modified peptide (450-fold).
Having defined the assembly mechanism of the heteroternary
complex and associated aﬃnity constants, we sought suitable
analytical procedures for its characterization. A separation techni-
que was considered most appropriate for the identification of
potential side-products such as unconjugated protein species. We
used asymmetric flow field flow fractionation (AF4) given its prior
application for polymeric host–guest complexes.27 For the AF4
method, we changed the protein used in the host–guest assembly
to the third fibronectin type III domain of human tenascin C
(Tn3).28 Tn3 is a small (13 kDa), monomeric protein and therefore
shows a much higher proportional change in molecular size upon
host–guest assembly with the peptide compared to the Fc domain
(51 kDa), improving the separation of products by AF4. We
expressed the Tn3 domain with a genetically introduced Trp guest
at the N-terminus followed by the tetraglycine–serine spacer and
assembled it with the cRGD-MVCCB[8] precomplex, resulting in the
cRGD-MVCCB[8]CTrp–Tn3 ternary complex. The free Trp–Tn3
domain was separated from its peptide-bound state at different
molar ratios of cRGD-MVCCB[8]:Trp–Tn3 (Fig. S8, ESI†).
For molar ratios of cRGD-MVCCB[8]:Trp–Tn3 4 1, repre-
senting saturation of the Trp–Tn3 domain, no further shift
towards later elution times was observed, which demonstrates
that the ternary complex did not significantly disassemble
during separation. To corroborate the AF4 data, we applied
a light scattering approach (Fig. S9, ESI†) to independently
confirm the change in molecular weight (Mw) from the free
Trp–Tn3 domain (14.5  0.2 kDa) towards the assembled
cRGD-MVCCB[8]CTrp–Tn3 ternary complex (16.4  0.3 kDa),
which is in good agreement with the theoretically calculated
values of 14.2 and 16.3 kDa, respectively.
Having confirmed that the heteroternary complex is forming
and stable through purification, we further studied the on/oﬀ
kinetics of the supramolecular assembly. Therefore, stopped-
flow experiments were performed in which the decrease in
intrinsic fluorescence of the 2nd guest Trp upon assembly of
Trp-Fc with cRGD-MVCCB[8] was followed spectroscopically
(Fig. S10, ESI†). Pseudo-first order assembly conditions were
established over three temperatures by altering the molar ratio
of cRGD-MVCCB[8]:Trp-Fc, with at least a 5-fold excess of the
1st guest while keeping the concentration of Trp-Fc constant
(Fig. S10C, ESI†). We subsequently applied the method described
by Appel et al.29 to calculate the association and dissociation rate
constants (ka and kd) at the respective temperatures (Table 1).
Due to the fast kinetics of the ternary complex formation, we
were only able to determine kinetic rate constants at tempera-
tures below 15 1C. However, the calculation of the Arrhenius
activation energies of association (Eaa; 29  4 kJ mol1) and
dissociation (Ead; 34  3 kJ mol1)29 allowed us to extrapolate
the rate constants at higher temperatures, notably 37 1C, both
more relevant and predictive of behaviour in vivo.
Interestingly, both ka and kd become faster to almost the
same degree with increasing temperature, thereby resulting in
only a minimal temperature eﬀect on the equilibrium binding
constants. We were able to confirm the temperature stability of
Fig. 3 Interaction of (cRGD-MVCCB[8])2CTrp-Fc with its molecular tar-
get integrin avb3. Binding of (cRGD-MVCCB[8])2CTrp-Fc to immobilised
integrins was followed by surface plasmon resonance (SPR). Competing
RGD peptide was spiked into the assembled complex at 0.2 and 1 mM
leading to reduced binding levels similar to when CB[8] was omitted in the
complex assembly (without CB[8], dark blue line). Background binding
levels are represented by an assembled complex of Trp-Fc with CB[8] and
G5-MV. Arrows indicate start and end of the sample injections.
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the complex independently by ITC (Table 1). Our obtained
kinetics for ternary complex formation with Trp mainly diﬀer
in faster association rate constants (410-fold) as compared to
previous studies using polymers with naphthalene as 2nd
guests,29 which also translates into roughly 10-fold higher
equilibrium binding constants.
To demonstrate retained fully reversible RGD-mediated
binding of the tertiary complex to integrin, the binding kinetics
were characterised by surface plasmon resonance (SPR). We
tested the binding of the (cRGD-MVCCB[8])2CTrp-Fc complex
to immobilised integrin avb3 (Fig. 3). As a negative control
we conjugated Trp-Fc to a pentaglycine-MV peptide (G5-MV,
Fig. S1A, ESI†) resulting in (G5-MVCCB[8])2CTrp-Fc which lacks
the integrin-binding motif. A strong response was observed upon
incubating integrins with (cRGD-MVCCB[8])2CTrp-Fc whereas
an exchange of the peptide to G5-MV led to only a minor,
unspecific response. Additionally, we were able to show that
spiking of (cRGD-MVCCB[8])2CTrp-Fc with increasing concen-
trations of integrin-competing linear RGD led to a decrease in
response levels similar to when CB[8] was omitted in the
complex thereby demonstrating the reversibility of integrin-
binding by (cRGD-MVCCB[8])2CTrp-Fc.
We successfully applied CB[8]-mediated host–guest chemistry for
the selective, heterodimeric conjugation of small syntheticmolecules
to recombinant proteins without the prior chemical modification of
the protein. The detailed knowledge about the thermodynamics and
kinetics presented here will enable the evolution of small molecule–
protein complexes, e.g. optimisation of protein–CB[8] interaction
motifs,30 inclusion of repetitive, zipper-like host–guest complexes16
or applying strategies to decrease the entropic penalty of the
assembly.8,9 We anticipate that this modular approach has
transformative potential in drug design and development,
offering increased freedom to select the protein and small
molecule components of a drug conjugate to impart advantages
regarding potency, stability and targeted delivery.
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and Christel Veyssier for help with the light scattering experi-
ments. RJG was supported by the MedImmune post-doctoral
program. SS was supported by ERC Starting Investigator grant
ASPiRe (No. 240629).
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